Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ponatinib
- Development stage
- Approved
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ponatinib is a small molecule tyrosine kinase inhibitor used primarily for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), especially in patients who are resistant or intolerant to prior therapies. It is particularly effective against CML with the T315I mutation, which confers resistance to other BCR-ABL inhibitors. Ponatinib works by inhibiting multiple kinases, most notably BCR-ABL (including T315I mutant), as well as VEGFR, PDGFR, FGFR, EPH receptors, SRC family kinases, KIT, RET, TIE2, and FLT3. The drug was developed by Ariad Pharmaceuticals and is marketed under the brand name Iclusig.
- Brand names
- Iclusig
- Other names
- ponatinibAP24534AP-24534AP 24534
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)SFK (SRC family kinases)TEK (Tie2)VEGFR (VEGFR family)EPH (EPH receptor family)FGFR (FGFR family)
Beyond the preview
Go deeper on ponatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ponatinib.